83 related articles for article (PubMed ID: 21719976)
1. [Assessment of vertebral fractures on radiographs and the effects of drug therapy on vertebral fractures].
Soen S
Clin Calcium; 2011 Jul; 21(7):963-9. PubMed ID: 21719976
[TBL] [Abstract][Full Text] [Related]
2. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.
Genant HK; Jergas M; Palermo L; Nevitt M; Valentin RS; Black D; Cummings SR
J Bone Miner Res; 1996 Jul; 11(7):984-96. PubMed ID: 8797120
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.
Prevrhal S; Krege JH; Chen P; Genant H; Black DM
Curr Med Res Opin; 2009 Apr; 25(4):921-8. PubMed ID: 19250060
[TBL] [Abstract][Full Text] [Related]
4. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
5. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
[TBL] [Abstract][Full Text] [Related]
6. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four morphometric definitions and a semiquantitative consensus reading for assessing prevalent vertebral fractures.
Grados F; Roux C; de Vernejoul MC; Utard G; Sebert JL; Fardellone P
Osteoporos Int; 2001; 12(9):716-22. PubMed ID: 11605736
[TBL] [Abstract][Full Text] [Related]
8. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
[TBL] [Abstract][Full Text] [Related]
9. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Semi-quantitative method in the assessment of vertebral fracture].
Ito M; Chiba K
Clin Calcium; 2008 Aug; 18(8):1120-6. PubMed ID: 18677049
[TBL] [Abstract][Full Text] [Related]
10. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures.
Wu CY; Li J; Jergas M; Genant HK
Osteoporos Int; 1995; 5(5):354-70. PubMed ID: 8800786
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
12. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
14. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
[TBL] [Abstract][Full Text] [Related]
15. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
16. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
17. Assessment of vertebral fractures in osteoporosis research.
Genant HK
J Rheumatol; 1997 Jun; 24(6):1212-4. PubMed ID: 9195538
[TBL] [Abstract][Full Text] [Related]
18. Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women.
Fukunaga M; Nakamura T; Shiraki M; Kuroda T; Ohta H; Hosoi T; Orimo H
J Bone Miner Metab; 2004; 22(2):104-10. PubMed ID: 14999520
[TBL] [Abstract][Full Text] [Related]
19. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
20. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
